- Home
- HSTM vs ADPT Comparison
HSTM vs ADPT Comparison
Compare HSTM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- ADPT
- Stock Information
- Founded
- HSTM 1990
- ADPT 2009
- Country
- HSTM United States
- ADPT United States
- Employees
- HSTM N/A
- ADPT N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSTM Technology
- ADPT Health Care
- Exchange
- HSTM Nasdaq
- ADPT Nasdaq
- Market Cap
- HSTM 960.2M
- ADPT 1.1B
- IPO Year
- HSTM 2000
- ADPT 2019
- Fundamental
- Price
- HSTM $32.39
- ADPT $7.33
- Analyst Decision
- HSTM Hold
- ADPT Strong Buy
- Analyst Count
- HSTM 2
- ADPT 5
- Target Price
- HSTM $30.00
- ADPT $9.40
- AVG Volume (30 Days)
- HSTM 170.6K
- ADPT 2.4M
- Earning Date
- HSTM 04-29-2025
- ADPT 05-01-2025
- Dividend Yield
- HSTM 0.38%
- ADPT N/A
- EPS Growth
- HSTM 32.31
- ADPT N/A
- EPS
- HSTM 0.66
- ADPT N/A
- Revenue
- HSTM $291,646,000.00
- ADPT $178,957,000.00
- Revenue This Year
- HSTM $6.51
- ADPT $21.20
- Revenue Next Year
- HSTM $5.69
- ADPT $22.06
- P/E Ratio
- HSTM $49.19
- ADPT N/A
- Revenue Growth
- HSTM 4.51
- ADPT 5.10
- 52 Week Low
- HSTM $23.92
- ADPT $2.28
- 52 Week High
- HSTM $34.24
- ADPT $9.01
- Technical
- Relative Strength Index (RSI)
- HSTM 53.84
- ADPT 43.95
- Support Level
- HSTM $30.38
- ADPT $7.38
- Resistance Level
- HSTM $32.82
- ADPT $8.30
- Average True Range (ATR)
- HSTM 0.93
- ADPT 0.75
- MACD
- HSTM 0.14
- ADPT -0.04
- Stochastic Oscillator
- HSTM 85.62
- ADPT 33.85
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).